Top 25 Biotech Companies based on Market Capitalization

by Alex Philippidis

Below are the top 25 biotechnology companies based on market capitalization at the end of the second quarter 2012, and Q2 2011, calculated by multiplying the number of outstanding shares by the share price. U.S. companies generally report their numbers of outstanding shares in their 10-Q quarterly earnings filings with the Securities & Exchange Commission. Companies based outside the U.S. either disclose market cap directly, or their numbers of shares “in issue” or “in free issue” in half-year and full-year results disclosures.

For all companies, closing share prices as of the dates of their outstanding-shares figures can be found through any of several free stock information websites. Figures of non-U.S. companies were converted to U.S. dollars from various currencies. 2012 market cap for companies reporting numbers of outstanding shares as of June 30 was calculated using share prices as of June 29, since markets were closed on June 30.

#25. Seattle Genetics

2012 Market Cap: $2.92 billion (8/2: 118,207,214 shares at price $24.72)

2011 Market Cap: $1.89 billion (8/1: 114,730,639 shares at price $16.45)

% Change: 54.5%

#24. Ariad Pharmaceuticals

2012 Market Cap: $3.18 billion (7/31: 166,204,624 shares * price $19.13)

2011 Market Cap: $1.58 billion (7/29: 132,547,176 shares * price $11.89)

% Change: 101.3%

#23. Medivation

2012 Market Cap: $3.65 billion (8/3: 36,832,178 shares * price $99.04)

2011 Market Cap: $683.85 million (8/3: 34,907,994 shares *price $19.59)

% Change: 433.4%

#22. Ranbaxy Laboratories

2012 Market Cap: $3.71 billion (6/30: 422,112,588 shares * price Rs. 490.55)

2011 Market Cap: $4.08 billion (6/30: 421,363,230 shares * price Rs. 540.35)

% Change: -9.1%

#21. Warner Chilcott

2012 Market Cap: $4.49 billion (7/20: 250,482,397 shares * price $17.91)

2011 Market Cap: $5.69 billion (7/25: 254,075,621 shares * price $22.40)

% Change: -21.1%

#20. Actelion

2012 Market Cap: $4.65 billion (6/30: 116,860,000 shares * price €32.20)

2011 Market Cap: $5.02 billion (6/30: 119,164,000 shares * price €34.09)

% Change: -7.4%

#19. Onyx Pharmaceuticals¹

2012 Market Cap: $5.06 billion (7/27: 65,095,777 shares * price $77.73)

2011 Market Cap: $2.10 billion (7/29: 63,544,578 shares * price $32.98)

% Change: 141.0%

#18. Amylin Pharmaceuticals^1,2

2012 Market Cap: $5.06 billion (7/27: 164,283,038 shares * price $30.80)

2011 Market Cap: $1.74 billion (7/27: 145,893,374 shares * price $11.96)

% Change: 190.8%

#17. Dr. Reddy’s Laboratories^3,4

2012 Market Cap: $5.35 billion (3/31: 169,470,729 shares * price: Rs 1758.65)

2011 Market Cap: $5.03 billion (3/31: 169,128,649 shares * price: Rs. 1638.55)

% Change: 6.4%

#16. BioMarin Pharmaceuticals⁴

2012 Market Cap: $5.35 billion (7/13: 123,555,244 shares * price $43.30)

2011 Market Cap: $3.32 billion (7/15: 111,827,290 shares * price $29.69)

% Change: 61.1%

#15. Elan

2012 Market Cap: $8.63 billion (6/30: 591.3 million shares *price $14.59)

2011 Market Cap: $6.67 billion (6/30: 586.4 million shares *price $11.37)

% Change: 29.4%

#14. UCB

2012 Market Cap: $8.77 billion (6/30: 179.1 million shares * price €39.84)

2011 Market Cap: $6.84 billion (6/30: 179.5 million shares * price €30.99)

% Change: 28.2%

#13. Forest Laboratories

2012 Market Cap: $8.87 billion (8/8: 265,693,834 shares * price $33.40)

2011 Market Cap: $9.09 billion (8/8: 274,555,930 shares * price $33.12)

% Change: -2.4%

#12. Regeneron

2012 Market Cap: $11.30 billion (7/13: 96,044,622 shares * price $117.64)

2011 Market Cap: $5.09 billion (7/15: 91,626,617 shares * price $55.59)

% Change: 122.0%

#11. Vertex Pharmaceuticals

2012 Market Cap: $10.64 billion (7/27: 215,807,482 shares * price $49.32)

2011 Market Cap: $10.79 billion (7/29: 208,087,899 shares * price $51.86)

% Change: -1.4%

#10. Alexion

2012 Market Cap: $18.85 billion (7/24: 193,059,462 shares * price $97.62)

2011 Market Cap: $10.48 billion (7/29: 184,530,093 shares * price $56.80)

% Change: 79.9%

#9. CSL

2012 Market Cap: $21.11 billion (A$20.099 billion)

2011 Market Cap: $18.33 billion (A$17.454 billion)

% Change: 15.2%

#8. Merck KGaA

2012 Market Cap: $21.16 billion (6/30: 217,388,939 shares * price €78.72)

2011 Market Cap: $20.14 billion (6/30: 217,388,939 shares * price €74.94)

% Change: 5.1%

#7. Celgene

2012 Market Cap: $28.38 billion (7/23: 431,423,976 shares * price $65.78)

2011 Market Cap: $27.52 billion (7/26: 458,805,956 shares * price $59.99)

% Change: 3.1%

#6. Baxter

2012 Market Cap: $32.27 billion (7/30: 547,231,164 shares * price $58.97)

2011 Market Cap: $33.36 billion (7/28: 568,256,444 shares * price $58.70)

% Change: -3.3%

#5. Teva Pharmaceutical Industries

2012 Market Cap: $34.23 billion (6/30: 868,000,000 shares * price $39.44)

2011 Market Cap: $42.96 billion (6/30: 891,000,000 shares * price $48.22)

% Change: -20.3%

#4. Biogen Idec

2012 Market Cap: $34.26 billion (7/18: 236,346,955 shares * price $144.96)

2011 Market Cap: $25.60 billion (7/22: 242,545,771 shares * price $105.56)

% Change: 33.8%

#3. Gilead Sciences

2012 Market Cap: $40.16 billion (7/20: 756,568,507 shares * price $53.08)

2011 Market Cap: $32.68 billion (7/29: 771,455,146 shares * price $42.36)

% Change: 28.5%

#2. Amgen

2012 Market Cap: $60.09 billion (7/25: 770,768,879 shares * price $77.96)

2011 Market Cap: $49.72 billion (7/27: 924,091,356 shares * price $53.80)

% Change: 20.9%

#1. Novo Nordisk

2012 Market Cap: $76.92 billion (6/30: DKK 549.1 million * price DKK 848.50)

2011 Market Cap: $60.09 billion (6/30: DKK 569.1 million * price DKK 639.50)

% Change: 28.0%

NOTES:

¹ Amylin Pharmaceuticals was listed ahead of Onyx Pharmaceuticals based on calculated market cap of $5.059,917,570.40, compared with $5,059,894,746.21.
² Acquired by Bristol-Myers Squibb in a $7 billion deal completed Aug. 8.
³ Market cap figures calculated as of March 31, since outstanding shares figures were published in company’s annual report but not in Q1 results materials.
⁴ Dr. Reddy’s Laboratories was listed ahead of BioMarin Pharmaceuticals based on calculated market cap of $5,349,942,065.20, compared with $5,345,899,863.0831.

Fuente: Genetic Engineering & Biotechnology News